Literature DB >> 19457119

Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity.

David M Thomas1, Dina M Francescutti-Verbeem, Donald M Kuhn.   

Abstract

Methamphetamine (METH) is a neurotoxic drug of abuse that damages the dopamine (DA) neuronal system in a highly delimited manner. The brain structure most affected by METH is the caudate-putamen (CPu) where long-term DA depletion and microglial activation are most evident. Even damage within the CPu is remarkably heterogenous with lateral and ventral aspects showing the greatest deficits. The nucleus accumbens (NAc) is largely spared of the damage that accompanies binge METH intoxication. Increases in cytoplasmic DA produced by reserpine, L-DOPA or clorgyline prior to METH uncover damage in the NAc as evidenced by microglial activation and depletion of DA, tyrosine hydroxylase (TH), and the DA transporter. These effects do not occur in the NAc after treatment with METH alone. In contrast to the CPu where DA, TH, and DA transporter levels remain depleted chronically, DA nerve ending alterations in the NAc show a partial recovery over time. None of the treatments that enhance METH toxicity in the NAc and CPu lead to losses of TH protein or DA cell bodies in the substantia nigra or the ventral tegmentum. These data show that increases in cytoplasmic DA dramatically broaden the neurotoxic profile of METH to include brain structures not normally targeted for damage by METH alone. The resistance of the NAc to METH-induced neurotoxicity and its ability to recover reveal a fundamentally different neuroplasticity by comparison to the CPu. Recruitment of the NAc as a target of METH neurotoxicity by alterations in DA homeostasis is significant in light of the important roles played by this brain structure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19457119      PMCID: PMC4821503          DOI: 10.1111/j.1471-4159.2009.06094.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  84 in total

1.  Striatal and cortical NMDA receptors are altered by a neurotoxic regimen of methamphetamine.

Authors:  A J Eisch; S J O'Dell; J F Marshall
Journal:  Synapse       Date:  1996-03       Impact factor: 2.562

2.  Tyrosine hydroxylase: purification from PC-12 cells, characterization and production of antibodies.

Authors:  D M Kuhn; M L Billingsley
Journal:  Neurochem Int       Date:  1987       Impact factor: 3.921

Review 3.  New insights into the mechanism of action of amphetamines.

Authors:  Annette E Fleckenstein; Trent J Volz; Evan L Riddle; James W Gibb; Glen R Hanson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

4.  A multisubstrate mechanism of striatal dopamine uptake and its inhibition by cocaine.

Authors:  J S McElvain; J O Schenk
Journal:  Biochem Pharmacol       Date:  1992-05-28       Impact factor: 5.858

5.  Methamphetamine rapidly decreases vesicular dopamine uptake.

Authors:  J M Brown; G R Hanson; A E Fleckenstein
Journal:  J Neurochem       Date:  2000-05       Impact factor: 5.372

6.  Mechanisms underlying methamphetamine-induced dopamine transporter complex formation.

Authors:  Gregory C Hadlock; Anthony J Baucum; Jill L King; Kristen A Horner; Glen A Cook; James W Gibb; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2009-01-13       Impact factor: 4.030

7.  Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine.

Authors:  M J LaVoie; T G Hastings
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

8.  Methamphetamine causes microglial activation in the brains of human abusers.

Authors:  Yoshimoto Sekine; Yasuomi Ouchi; Genichi Sugihara; Nori Takei; Etsuji Yoshikawa; Kazuhiko Nakamura; Yasuhide Iwata; Kenji J Tsuchiya; Shiro Suda; Katsuaki Suzuki; Masayoshi Kawai; Kiyokazu Takebayashi; Shigeyuki Yamamoto; Hideo Matsuzaki; Takatoshi Ueki; Norio Mori; Mark S Gold; Jean L Cadet
Journal:  J Neurosci       Date:  2008-05-28       Impact factor: 6.167

9.  Tyrosine hydroxylase mRNA concentration in midbrain dopaminergic neurons is differentially regulated by reserpine.

Authors:  G M Pasinetti; D G Morgan; S A Johnson; S L Millar; C E Finch
Journal:  J Neurochem       Date:  1990-11       Impact factor: 5.372

10.  Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat.

Authors:  D Stanic; D I Finkelstein; D W Bourke; J Drago; M K Horne
Journal:  Eur J Neurosci       Date:  2003-09       Impact factor: 3.386

View more
  21 in total

1.  A mouse model of human repetitive mild traumatic brain injury.

Authors:  Michael J Kane; Mariana Angoa-Pérez; Denise I Briggs; David C Viano; Christian W Kreipke; Donald M Kuhn
Journal:  J Neurosci Methods       Date:  2011-09-12       Impact factor: 2.390

2.  The role of endogenous serotonin in methamphetamine-induced neurotoxicity to dopamine nerve endings of the striatum.

Authors:  David M Thomas; Mariana Angoa Pérez; Dina M Francescutti-Verbeem; Mrudang M Shah; Donald M Kuhn
Journal:  J Neurochem       Date:  2010-09-06       Impact factor: 5.372

3.  Blockade and reversal of swimming-induced paralysis in C. elegans by the antipsychotic and D2-type dopamine receptor antagonist azaperone.

Authors:  Osama Refai; Randy D Blakely
Journal:  Neurochem Int       Date:  2018-05-22       Impact factor: 3.921

4.  Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation.

Authors:  Gregory C Hadlock; Pei-Wen Chu; Elliot T Walters; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2010-07-09       Impact factor: 4.030

5.  3,4-Methylenedioxypyrovalerone prevents while methylone enhances methamphetamine-induced damage to dopamine nerve endings: β-ketoamphetamine modulation of neurotoxicity by the dopamine transporter.

Authors:  John H Anneken; Mariana Angoa-Pérez; Donald M Kuhn
Journal:  J Neurochem       Date:  2015-03-02       Impact factor: 5.372

Review 6.  Nucleus accumbens invulnerability to methamphetamine neurotoxicity.

Authors:  Donald M Kuhn; Mariana Angoa-Pérez; David M Thomas
Journal:  ILAR J       Date:  2011

7.  Assessing the role of dopamine in the differential neurotoxicity patterns of methamphetamine, mephedrone, methcathinone and 4-methylmethamphetamine.

Authors:  John H Anneken; Mariana Angoa-Perez; Girish C Sati; David Crich; Donald M Kuhn
Journal:  Neuropharmacology       Date:  2017-08-26       Impact factor: 5.250

8.  Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence.

Authors:  Isabelle Boileau; Tina McCluskey; Junchao Tong; Yoshiaki Furukawa; Sylvain Houle; Stephen J Kish
Journal:  Neuropsychopharmacology       Date:  2015-08-31       Impact factor: 7.853

9.  Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA.

Authors:  Mariana Angoa-Pérez; Michael J Kane; Denise I Briggs; Dina M Francescutti; Catherine E Sykes; Mrudang M Shah; David M Thomas; Donald M Kuhn
Journal:  J Neurochem       Date:  2013-01-08       Impact factor: 5.372

10.  Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration : early loss of TH in striosomes after methamphetamine.

Authors:  Noelia Granado; Sara Ares-Santos; Esther O'Shea; Carlos Vicario-Abejón; M Isabel Colado; Rosario Moratalla
Journal:  Neurotox Res       Date:  2009-09-04       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.